| Bioactivity | GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM[1]. |
| Invitro | GP(33-41) sensitizes MC57 and T2-Db cells to lysis with ED50s of 0.9±0.6 and 2.5±0.7 nM[1]. The interaction between T cell receptors (TCR) and peptide-major histocompatibility complex (pMHC) antigens can lead to varying degrees of agonism (T cell activation), or antagonism. The P14 TCR recognises the lymphocytic choriomeningitis virus (LCMV)-derived peptide, GP(33-41) (KAVYNFATC), presents in the context of H-2D[2]. |
| Name | GP(33-41) |
| CAS | 161928-86-5 |
| Sequence | Lys-Ala-Val-Tyr-Asn-Phe-Ala-Thr-Cys |
| Shortening | KAVYNFATC |
| Formula | C46H69N11O13S |
| Molar Mass | 1016.17 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
GP(33-41)
CAS: 161928-86-5 F: C46H69N11O13S W: 1016.17
GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and ca
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.